Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 6/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FSHR | P23945 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 6/20 | 0.39 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30020826 | 1.00 | GCK (0.41) | GCKGSK3BDYRK1ATSHRFSHR | |
| SCHEMBL29988807 | 0.86 | GSK3B (0.40) | GCKGSK3BDYRK1ATSHRFSHR | |
| SCHEMBL23612124 | 0.86 | GSK3B (0.40) | GCKGSK3BDYRK1ATSHRFSHR | |
| SCHEMBL23612044 | 0.85 | GCK (0.45) | GCKGSK3BDYRK1ACNR2TRPC6 | |
| SCHEMBL23612235 | 0.81 | TSHR (0.38) | GCKGSK3BDYRK1ATSHRFSHR | |
| SCHEMBL30089383 | 0.81 | TSHR (0.38) | GCKGSK3BDYRK1ATSHRFSHR | |
| SCHEMBL30021227 | 0.78 | TRPC6 (0.46) | CNR2TRPC6 | |
| SCHEMBL23612054 | 0.78 | TRPC6 (0.46) | CNR2TRPC6 | |
| SCHEMBL23612087 | 0.77 | TRPC6 (0.46) | CNR2TRPC6 | |
| SCHEMBL2116624 | 0.76 | GSK3B (0.44) | GCKGSK3BDYRK1AAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115274-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-13 | — | — | US | disclosed |
| EP-4085061-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-115279770-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2021138419-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC, (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115274-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | GCK 1972/4885GSK3B 487/4885DYRK1A 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.